Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Sinha B, Ghosal S

Obesity (Silver Spring, Md.)20 Jul 2025Cited by 8 (Europe PMC)

PMID40685589DOI10.1002/oby.24360PepBankPUB-40685589

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewEfficacy outcome
In a network meta-analysis of adults with overweight or obesity, retatrutide achieved mean weight loss equivalent to dual agonists and greater than GLP-1RAs.
In plain wordsIn a pooled analysis of trials, retatrutide led to weight loss similar to dual agonists and greater than GLP-1 drugs.
Peptide
Retatrutide
Outcome
DecreaseMean weight loss
Study
n: not reported in source
Comparator
GLP-1 receptor agonists; dual agonists
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean weight loss
−11 kg
retatrutide
Mean weight loss
−9 kg
GLP-1RAs
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
Report a problemFND-4068558901
02HumanSystematic reviewEfficacy outcome
In a network meta-analysis of adults with overweight or obesity, retatrutide was best at achieving at least 15% weight loss.
In plain wordsIn a pooled analysis of trials, retatrutide was the most likely of the drugs compared to reach a weight loss of 15% or more.
Peptide
Retatrutide
Outcome
IncreaseAchievement of 15% or more weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Odds ratio for weight loss of at least 15%
54.6 odds ratio
retatrutide
Source sentences
Summary
with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
Report a problemFND-4068558902
03HumanSystematic reviewSafety outcome
In a network meta-analysis of adults with overweight or obesity, retatrutide had the highest risk of adverse events.
In plain wordsIn a pooled analysis of trials, retatrutide had the highest risk of side effects among the drugs compared.
Peptide
Retatrutide
Outcome
IncreaseAdverse event risk
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Retatrutide had the highest AE risk.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
Report a problemFND-4068558903

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1 receptor agonists (including semaglutide) achieved a mean weight loss of 9.0 kg, less than retatrutide and dual agonists (11.0 kg).
In plain wordsIn adults with overweight or obesity, the GLP-1 drug class as a group gave a mean weight loss of 9.0 kg, less than dual agonists.
Peptide
Semaglutide
Outcome
DecreaseMean weight loss, pooled GLP-1RAs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean weight loss
−9 kg
GLP-1RAs
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4068558904
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1 receptor agonists (including liraglutide) achieved a mean weight loss of 9.0 kg, less than retatrutide and dual agonists (11.0 kg).
In plain wordsIn adults with overweight or obesity, the GLP-1 drug class as a group gave a mean weight loss of 9.0 kg, less than dual agonists.
Peptide
Liraglutide
Outcome
DecreaseMean weight loss, pooled GLP-1RAs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean weight loss
−9 kg
GLP-1RAs
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4068558905
06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled dual agonists (including tirzepatide) achieved a mean weight loss of 11.0 kg, more than GLP-1 receptor agonists (9.0 kg).
In plain wordsIn adults with overweight or obesity, the dual-agonist drug class as a group gave a mean weight loss of 11.0 kg, more than GLP-1 drugs.
Peptide
Tirzepatide
Outcome
DecreaseMean weight loss, pooled dual agonists
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Mean weight loss
−11 kg
dual agonists
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4068558906
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1 receptor agonists (including semaglutide) raised the odds of 15% or more weight loss (OR 9.0).
In plain wordsIn adults with overweight or obesity, the GLP-1 drug class as a group made weight loss of 15% or more more likely.
Peptide
Semaglutide
Outcome
IncreaseAchievement of 15% or more weight loss, pooled GLP-1RAs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Odds ratio, weight loss of 15% or more
9 OR
GLP-1RAs
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP-1RAs followed (OR 16.4 and 9.0, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4068558907
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled GLP-1 receptor agonists (including liraglutide) raised the odds of 15% or more weight loss (OR 9.0).
In plain wordsIn adults with overweight or obesity, the GLP-1 drug class as a group made weight loss of 15% or more more likely.
Peptide
Liraglutide
Outcome
IncreaseAchievement of 15% or more weight loss, pooled GLP-1RAs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Odds ratio, weight loss of 15% or more
9 OR
GLP-1RAs
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP-1RAs followed (OR 16.4 and 9.0, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4068558908
09HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with overweight or obesity, pooled dual agonists (including tirzepatide) raised the odds of 15% or more weight loss (OR 16.4).
In plain wordsIn adults with overweight or obesity, the dual-agonist drug class as a group made weight loss of 15% or more more likely.
Peptide
Tirzepatide
Outcome
IncreaseAchievement of 15% or more weight loss, pooled dual agonists
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Odds ratio, weight loss of 15% or more
16.4 OR
dual agonists
Source sentences
Summary
Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP-1RAs followed (OR 16.4 and 9.0, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4068558909
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a meta-regression, type 2 diabetes reduced weight loss by 4.338 kg for pooled GLP-1 receptor agonists (including semaglutide).
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group led to 4.338 kg less weight loss.
Peptide
Semaglutide
Outcome
DecreaseEffect of type 2 diabetes on weight loss, pooled GLP-1RAs (meta-regression)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Reduction in weight loss with T2DM
4.338 kg
GLP-1RAs
Source sentences
Summary
Meta-regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP-1RAs and 5.016 kg for dual agonists
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4068558910
11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-regression, type 2 diabetes reduced weight loss by 4.338 kg for pooled GLP-1 receptor agonists (including liraglutide).
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class as a group led to 4.338 kg less weight loss.
Peptide
Liraglutide
Outcome
DecreaseEffect of type 2 diabetes on weight loss, pooled GLP-1RAs (meta-regression)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Reduction in weight loss with T2DM
4.338 kg
GLP-1RAs
Source sentences
Summary
Meta-regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP-1RAs and 5.016 kg for dual agonists
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4068558911
12HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In a meta-regression, type 2 diabetes reduced weight loss by 5.016 kg for pooled dual agonists (including tirzepatide).
In plain wordsIn adults with type 2 diabetes, the dual-agonist drug class as a group led to 5.016 kg less weight loss.
Peptide
Tirzepatide
Outcome
DecreaseEffect of type 2 diabetes on weight loss, pooled dual agonists (meta-regression)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Reduction in weight loss with T2DM
5.016 kg
dual agonists
Source sentences
Summary
Meta-regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP-1RAs and 5.016 kg for dual agonists
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a systematic review and Bayesian network meta-analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m²), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4068558912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 6 to 41Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Versions 2 to 5
9 Oct 2026, 03:07 UTC
The same notice was added 4 times, first on 9 Oct 2026, 03:05 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC